Vertex Pharmaceuticals Surges to 150th in Trading Volume as Gene Therapy Collaborations and Pipeline Progress Fuel 0.76% Rally

On August 28, 2025, Vertex Pharmaceuticals (VRTX) traded with a volume of $0.60 billion, ranking 150th in market activity. The stock rose 0.76%, driven by progress in its gene therapy collaborations and pipeline advancements.

Vertex’s partnership with CRISPR Therapeutics remains a key focus, particularly for Casgevy, a CRISPR/Cas9-based therapy approved for sickle cell disease and beta thalassemia. In Q2 2025, Casgevy generated $30.4 million in revenue, doubling from the prior quarter. Vertex also activated over 115 treatment centers globally, with 29 patients infused by June 2025. This milestone underscores the therapy’s growing commercial traction despite early-stage challenges.

Vertex’s internal R&D efforts further highlight its therapeutic pipeline. The company is advancing VX-522, a CFTR mRNA therapy for cystic fibrosis, currently in Phase 1/2 trials, and VX-880, a potential treatment for Type 1 Diabetes. Collaborative programs with Moderna and Entrada Therapeutics add strategic depth, though no immediate revenue drivers are expected from these early-stage assets.

The recent expansion of Casgevy into in vivo gene editing, exemplified by CRISPR Therapeutics’ CTX310 trial targeting atherosclerosis, signals Vertex’s broader ambitions in genetic medicine. However, competition from chronic therapies and regulatory uncertainties pose risks to long-term growth.

Query limit exceeded.